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Abstract: In the elderly population, osteoporosis is a signiﬁ  cant clinical problem leading to 
disability and even death. Many patients remain untreated, despite effective therapies, because 
of patients’ unwillingness to take current therapies or inability to tolerate the therapies. For 
this reason, ongoing research continues to search for more effective and tolerable osteopo-
rosis agents. Bazedoxifene is a selective estrogen receptor modulator (SERM) currently in 
development for osteoporosis prevention and treatment. A new drug application (NDA) for 
postmenopausal osteoporosis prevention was recently submitted to the FDA. Preclinical and 
clinical studies with bazedoxifene demonstrate more tissue selectivity than other SERMs. 
In particular, bazedoxifene has minimal if any agonist activity in the uterus and is able to 
antagonize effects of estrogen on the uterus. Animal studies and early clinical studies suggest 
effects in the bone similar to other SERMs with prevention of postmenopausal bone loss. Until 
more data on efﬁ  cacy and safety are published, however, its role in osteoporosis is unknown. 
Keywords: osteoporosis, bazedoxifene, selective estrogen receptor modulator, postmenopause, 
prevention
Management of osteoporosis
Osteoporosis, most often resulting from accelerated bone resorption, leads to low 
bone mass and increased susceptibility to fragility fracture (Biskobing 2003). As 
the number of elderly increases in our population the prevalence of osteoporosis in-
creases. In the United States, 8 million women and 2 million men have osteoporosis 
(National Osteoporosis Foundation (NOF) 2006). Osteoporosis poses a signiﬁ  cant 
health problem worldwide; a 50 year old postmenopausal woman has a 40–50% risk 
of having an osteoporotic fracture in her lifetime (NOF 2006; Epstein 2006). Osteo-
porotic fractures can lead to signiﬁ  cant morbidity and mortality. Hip fractures have 
the most substantial consequences, resulting in loss of independence in up to 50% 
of patients (Schurch et al 1996; NOF 2006). In addition there is up to 24% mortality 
in the ﬁ  rst year after a hip fracture (Chrischilles et al 1991; Myers et al 1991; Block 
and Stubbs 1997). The cost to the health care system of treating hip fractures alone 
is substantial. Treatment of osteoporosis, thus, is aimed at preventing osteoporotic 
fractures, especially hip fractues. Management of postmenopausal osteoporosis to 
prevent fractures includes lifestyle changes, weight bearing exercise (McClung et al 
1996; Henderson et al 1998), calcium and vitamin D supplementation (Epstein 2006), 
and pharmacologic therapy. 
The majority of pharmacologic agents for osteoporosis are antiresorptives, acting 
to inhibit osteoclast development or action. Current antiresorptives for osteoporosis 
treatment include bisphosphonates, the selective estrogen receptor modulator (SERM) 
raloxifene, hormone replacement therapy (HRT), and calcitonin. The only available 
anabolic agent is teriparatide (recombinant PTH 1–34). Bisphosphonates are potent 
antiresorptives and currently are the mainstay of osteoporosis therapy. Both alendronate Clinical Interventions in Aging 2007:2(3) 300
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(Liberman et al 1995; Black et al 1996, 1999; Cummings 
et al 1998) and risedronate (Harris et al 1999; Reginster 
et al 2000; McClung et al 2001) have both been shown to 
signiﬁ  cantly decrease osteoporotic fractures in large, random-
ized, controlled trials. Alendronate, in multiple studies, has 
been shown to decrease vertebral fractures 44%–48% after 
3 years (Liberman et al 1995; Cummings et al 1998; Black 
et al 1999). In the Fracture Intervention Trial, women with 
preexisting vertebral fractures had a 51% decrease in hip 
fractures (Black et al 1999), women with no prior vertebral 
fracture and a femoral neck T score less than –2.5 had a 56% 
decrease in hip fractures after 4 years (Cummings et al 98). 
In two Vertebral Efﬁ  cacy with Risedronate Therapy (VERT) 
studies risedronate decreased vertebral fractures 41–49% 
after 3 years of treatment (Harris et al 1999; Reginster et al 
2000). Nonvertebral fractures decreased 30%–40% after 3 
years therapy in the VERT study (Harris et al 1999) and a 
separate hip fracture study (McClung et al 2001). Ibandronate 
is the newest bisphosphonate approved for prevention and 
treatment of osteoporosis. Phase III studies demonstrated a 
signiﬁ  cant 50% reduction in vertebral fractures with either 
daily or intermittent dosing (Chestnut et al 2004; Delmas 
et al 2004). However, in the overall group, no reduction in 
nonvertebral fractures was seen. In the group at highest risk 
for hip fracture, with a femoral neck T score less than –3, 
daily treatment led to a 69% decrease in nonvertebral frac-
tures (Delmas et al 2004). Oral bisphosphonates, however, 
are hampered by poor gastrointestinal absorption and risk for 
esophageal irritation or ulceration (Epstein 2006). Because 
of the poor absorption and to avoid prolonged esophageal 
exposure, patients are required to take bisphosphonates fast-
ing, in an upright position, with a full glass of water. These 
requirements often hamper compliance. Ibandronate has been 
approved for intravenous administration and can be used 
in those unable to tolerate or absorb oral bisphosphonates 
(Epstein 2006). In the Women’s Health Initiative (WHI) HRT 
was shown to be an effective treatment for osteoporosis (Ros-
souw et al 2002; Anderson et al 2004). Hip fractures were 
decreased 34–39% and vertebral fractures decreased 38%. 
But because of potential adverse outcomes noted in WHI, 
including increased thromboembolic disease, cardiovascular 
disease and breast cancer, HRT is not routinely recommended 
for osteoporosis treatment. In the Prevent Recurrence of 
Osteoporotic Fractures trial nasal calcitonin decreased ver-
tebral fractures 33% but did not demonstrate a decrease in 
nonvertebral fractures (Chestnut et al 2000). Teriparatide is 
presently the only osteoporosis agent available in the United 
States that stimulates bone formation. Teriparatide has been 
shown to signiﬁ  cantly decrease vertebral and nonvertebral 
fractures by 65% and 53% respectively (Neer et al 2001). 
Teriparatide use is currently approved by the FDA for 2 years 
of therapy (Epstein 2006). Product labeling for teriparatide 
currently includes a black box warning due to development 
of osteosarcoma in rats exposed to lifelong therapy (Forteo 
package insert). 
Raloxifene is the only SERM currently FDA approved 
for prevention and treatment of osteoporosis. SERMs 
have been developed to have estrogen agonist effects at 
the bone with antagonist effects at the breast and uterus 
(Miller 2001). The effects of raloxifene on bone density 
and metabolic bone markers are generally more modest than 
that seen with bisphosphonates. This raises the question of 
whether SERMS have selective effects on trabecular ver-
sus cortical bone (Epstein 2006). In the large osteoporosis 
fracture study, Multiple Outcomes of Raloxifene Evalua-
tion (MORE), vertebral fractures were decreased 37% after 
four years of raloxifene, 60 mg daily (Delmas et al 2002). 
A decrease in nonvertebral fractures was not seen; how-
ever, the study was not powered to detect an effect on hip 
fractures. Raloxifene is generally well tolerated, however 
there is an increase in hot ﬂ  ushes associated with it use. In 
addition, there is a 3-fold increase in venous thromboem-
bolic events associated with raloxifene use (Epstein 2006). 
Recent results of the Raloxifene Use for the Heart (RUTH) 
trial conﬁ  rmed the results of the MORE trial with a 35% 
decrease in vertebral fractures but no signiﬁ  cant effect on 
nonvertebral fractures (Barrett-Connor et al 2006). The 
RUTH trial did demonstrate a 33% lower incidence in breast 
cancer. However, there was no signiﬁ  cant effect of raloxi-
fene on any cardiovascular outcome despite improvement 
in the lipid proﬁ  le. In addition there was a 44% higher rate 
of venous thromboembolic events in the raloxifene group. 
Finally, the rate of fatal strokes was increased 49% in the 
raloxifene group. The decision to use raloxifene for man-
agement of osteoporosis has to weigh the beneﬁ  cial effects 
on vertebral fractures and breast cancer against the risk for 
venous thromboembolic events or fatal stroke. 
Numerous SERMS besides raloxifene are in develop-
ment including arzoxifene, bazedoxifene, and lasofoxifene 
(Biskobing 2003). SERMs function by binding to the ligand 
binding domain of the estrogen receptor, but because of con-
formational differences have varying effects on coregulatory 
proteins associated with tissue-speciﬁ  c gene transcription 
(Miller et al 2001). By altering the side chains on SERMs, 
binding and selectively are affected. In September 2005, 
the FDA gave Pﬁ  zer a non-approvable letter regarding Clinical Interventions in Aging 2007:2(3) 301
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lasofoxifene for postmenopausal osteoporosis prevention and 
in December 2005 gave a non-approvable letter for treatment 
of vaginal atrophy (Pﬁ  zer ﬁ  nancial statement 2005). A new 
drug application (NDA) for bazedoxifene was submitted to 
the FDA in June 2006.
Pharmacology and 
pharmacokinetics of bazedoxifene
Bazedoxifene is a novel, non-steroidal, indole-based SERM 
currently under development by Wyeth Pharmaceuticals 
(Gruber and Gruber 2004). It was developed using raloxi-
fene as a template with the benzothiophene core substituted 
by an indole ring (Gruber and Gruber 2004). Bazedoxifene 
binds to both ERα (IC50 23 ± 15 nM) and ERβ (IC50 89 ± 159 
nM) with high afﬁ  nity (Miller et al 2001). However, in vitro 
studies have demonstrated selective effects of bazedoxifene 
compared to estrogen. In cultured breast cancer (bMCF-7) 
cells bazedoxifene does not stimulate ERα mediated tran-
scriptional activity and acts as an antagonist to estradiol 
(Miller et al 2001). Similar results are seen in other cell 
lines including CHO (ovarian), HepG2 (hepatic) or GTI-7 
(neuronal) with bazedoxifene having no ERα agonist activ-
ity and acting as an antagonist to estradiol action (Komm 
et al 2005). However, bazedoxifene agonist activity can be 
seen with the hepatic lipase promoter with an EC50 of 100 
nM compared to estradiol which has an EC50 of 26 nM. In 
contrast, raloxifene does not have a detectable agonist effect 
on the hepatic lipase promoter (Komm et al 2005). Several 
pharmacokinetic studies have been performed in normal 
women. In a study designed to evaluate the metabolic clear-
ance of 14[C]bazedoxifene, a single 20 mg dose was given to 
six postmenopausal women. Metabolism of the drug was via 
glucuronidation with the major route of excretion via the fe-
ces (Chandrasekaran et al 2003). To study the bioavailability 
of bazedoxifene two oral formulations, a 10 mg tablet and 
two 5 mg capsules, and a 3 mg IV formulation were given 
to 18 postmenopausal women in a 3-way crossover design. 
Blood samples were collected for 168 hours after each dose. 
Each period was separated by 2 weeks. The absolute bioavail-
abilty of bazedoxifene was 6.2% for both oral formulations 
(Patat et al 2003). Finally, a study evaluated the longer term 
pharmacokinetics of multiple doses of bazedoxifene. In a 
randomized, crossover study 23 postmenopausal women 
were given multiple doses of bazedoxifene (5, 20, 40 mg) 
for 14 days. Maximum concentration was achieved in 1–2 
hours and t½ was approximately 28 hours. Protein binding was 
greater than 99%. Steady state concentrations were achieved 
by day 7 (Ermer et al 2003). 
Efﬁ  cacy studies 
Preclinical studies have evaluated effects of bazedoxifene on 
the bone and the breast as well as potential adverse effects on 
the uterus. In an immature rat model, bazedoxifene at a dose 
of 0.5 mg/kg increased uterine wet weight 35% compared 
to an 85% increase with raloxifene at the same dose and a 
300% increase in uterine weight with ethinyl estradiol at a 
dose of 10 μg/kg (Komm et al 2005). Despite the signiﬁ  cant 
increase in uterine weight with bazedoxifene treatment, there 
was no evidence for epithelial cell hyperplasia or myometrial 
hyperplasia with bazedoxifene compared to estradiol which 
stimulated more than a 3-fold increase in luminal cell height. 
In a similar immature rat study, 10 ug and 100 ug doses of 
bazedoxifene did not increase uterine wet weight and also 
was able to prevent the increased uterine wet weight seen with 
administration of 1 ug of estradiol (Miller et al 2001). Fur-
ther studies in ovarectomized rats have demonstrated dose-
dependent effects of bazedoxifene on bone similar to estrogen 
(Kharode et al 2005, Komm et al 2005). Ovarectomized rats 
treated with 0.3 mg/d bazedoxifene displayed maintenance 
of bone mass and bone strength similar to effects seen with 
2 μg/d ethinyl estradiol, 3 mg/d raloxifene, or sham operated 
animals (Komm et al 2005). In addition, total cholesterol lev-
els were signiﬁ  cantly lower with bazedoxifene treatment than 
in vehicle treated animals. To evaluate the potential effects of 
bazedoxifene on hot ﬂ  ushes, a morphine-addicted rat model 
of vasomotor changes and thermoregulation was used. In 
this model estradiol prevents a rise in tail skin temperature 
induced by naloxone (Komm et al 2005). Bazedoxifene does 
not act as an estrogen agonist in this model. With high dose 
bazedoxifene (10 mg/kg) the effect of estrogen is abrogated. 
However, with bone sparing doses of bazedoxifene there is 
no antagonism of estrogen effects on vasomotor instability. 
Further evaluation of the bone sparing effects of bazedoxi-
fene has been done in a monkey model. Ovariectomized 
monkeys were treated with placebo or increasing doses of 
bazedoxifene (0.2, 0.5, 1, 5, or 25 mg/kg/d) for 18 months. 
Treatment with the highest doses of bazedoxifene resulted 
in maintenance of BMD at the spine and proximal femur at 
pre-ovariectomy levels. Biomechanical strength, mineraliza-
tion, and structural parameters were not adversely affected 
by bazedoxifene treatment (Smith et al 2005).
There have also been animal studies evaluating the effects 
of combination treatment with estrogen and bazedoxifene. 
An immature rat model and 6 week ovariectomized rat model 
were treated with a bone sparing dose of CEE alone or in 
combination with bazedoxifene to evaluate effects on bone, 
uterus, and vasomotor instability (Komm et al 2003a; Komm Clinical Interventions in Aging 2007:2(3) 302
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et al 2003b). 7–10-fold the bone sparing dose of bazedoxi-
fene was needed to inhibit the effects of CEE on the uterus 
(Komm et al 2003a). However, this dose of bazedoxifene 
did not interfere with the improved vasomotor control elic-
ited by CEE. In a separate study ovariectomized rats were 
treated with CEE (2.5 mg/kg) alone or in combination with 
bazedoxifene (1–3mg/kg), lasofoxifene (0.1–1 mg/kg), or 
raloxifene (1–10 mg/kg) (Komm et al 2003b). After 6 weeks 
bone mineral density was similar in all groups. However, only 
the bazedoxifene was able to inhibit the increased uterine wet 
weight associated with CEE treatment. 
There are no published studies on the results of clinical 
osteoporosis fracture trials comparing bazedoxifene to pla-
cebo. Results of a phase II study have been presented at the 
American Society for Bone and Mineral Research in 2001. 
494 healthy, postmenopausal women were randomized to 3 
doses of bazedoxifene, placebo, or raloxifene for 3 months. 
A signiﬁ  cant decrease in metabolic bone markers was seen 
with bazedoxifene treatment compared to placebo (Ronkin 
et al 2001). The decrease in metabolic bone markers was 
comparable to the effect seen with raloxifene. A similar 
study in Chinese women was presented at the 2003 annual 
meeting of the International Osteoporosis Foundation. In 
this study 275 postmenopausal women were randomized 
to bazedoxifene (20 mg or 40 mg) versus placebo for 3 
months. Both doses of bazedoxifene resulted in a signiﬁ  cant 
decreases in metabolic bone markers: urine CTX decreased 
37%–42% compared to 25% with placebo; serum CTX 
decreased 34%–38% compared to 18% with placebo; urine 
NTX decreased 18%–30% compared to 13% with placebo 
and osteocalcin decreased 20% compared to 7% with placebo 
(Ling et al 2003). The effect of combination therapy with 
bazedoxifene plus conjugated equine estrogen (CEE) was 
evaluated in a phase II study. Women were treated with CEE 
alone or in combination with 10 or 20 mg of bazedoxifene. 
The increase in endometrial thickness was 3mm with CEE 
but only 1.5 mm and 1mm with the addition of 10 or 20 mg 
of bazedoxifene. Furthermore, the addition of bazedoxifene 
to CEE did not negate the decrease in hot ﬂ  ashes expected 
with CEE therapy (Gruber and Gruber 2004). Large phase III 
osteoporosis prevention and treatment studies are completed 
but results are not yet published. In addition phase III studies 
evaluating a combination of bazedoxifene plus CEE for os-
teoporosis treatment or menopausal symptoms are currently 
ongoing. Combination bazedoxifene/CEE is being pursued 
to provide the beneﬁ  ts of estrogen and a SERM on bone and 
lipid metabolism while avoiding increased hot ﬂ  ushes and 
the potential for breast and endometrial cancer. 
Safety and tolerability 
The effect of bazedoxifene on the endometrium has been 
evaluated. In a dose-ranging double-blind, randomized, 
placebo controlled study, 600 postmenopausal women were 
treated with bazedoxifene doses ranging from 2.5 mg to 40 
mg, 0.625 mg CEE, or placebo for 6 months (Ronkin et al 
2005). Change in endometrial thickness after 6 months of 
treatment with bazedoxifene was not signiﬁ  cantly different 
than placebo. On endometrial biopsy there was no evidence 
for endometrial hyperplasia. In addition, bazedoxifene was 
well tolerated; no women withdrew from the study due to 
hot ﬂ  ushes, leg cramps, or uterine bleeding. There was one 
case of superﬁ  cial thrombophlebitis. Another study evalu-
ated breast pain. 236 postmenopausal women were random-
ized to bazedoxifene (20 or 40 mg), or placebo for 6 months. 
The incidence of breast pain was not different compared to 
placebo in the 20 mg group and was signiﬁ  cant lower than 
placebo in the 40 mg group (Boudes et al 2003). 
Conclusion
In conclusion, bazedoxifene appears to have improved 
selectivity compared to other SERMs. Preclinical and clini-
cal studies suggest little to no stimulatory effects on uterine 
tissue and the ability to antagonize estrogen uterine effects. 
In addition, from the few published clinical studies available, 
bazedoxifene does not appear to increase hot ﬂ  ashes. Similar 
to raloxifene, in vitro studies suggests inhibitory effects at 
the breast although no long term clinical data has yet been 
released on effects on breast cancer rates. There is currently 
not enough published data to assess bazedoxifene’s effect 
on bone metabolism in postmenopausal women or the rate 
of adverse effects such as venous thromboembolic events. 
Until more data on efﬁ  cacy of bazedoxifene in osteoporosis 
prevention and treatment is published, its role in osteoporosis 
management cannot be determined. 
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